Precision BioSciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DTIL Nasdaq 2836 precisionbiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Precision BioSciences, Inc.

[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - May 21st, 2026 11:30 am
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 - May 21st, 2026 5:01 am
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting - May 14th, 2026 5:01 am
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts - May 13th, 2026 5:07 am
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates - May 5th, 2026 6:25 am
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update - May 5th, 2026 5:01 am
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - Apr 30th, 2026 5:01 am
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study - Apr 29th, 2026 5:01 am
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting - Apr 28th, 2026 5:01 am
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains? - Apr 27th, 2026 6:18 am
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Apr 24th, 2026 5:01 am
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 - Apr 22nd, 2026 5:01 am
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock? - Apr 20th, 2026 5:59 am
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries - Apr 15th, 2026 5:01 am
Should You Buy Precision BioSciences (DTIL) After Golden Cross? - Apr 14th, 2026 7:55 am
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference - Apr 8th, 2026 5:01 am
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Mar 12th, 2026 6:15 am
Precision BioSciences: Q4 Earnings Snapshot - Mar 12th, 2026 5:15 am
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - Mar 12th, 2026 5:00 am
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - Mar 11th, 2026 5:01 am